Clinical trial PYTHIA IBCSG 53-14 / BIG 14-04
PYTHIA IBCSG 53-14 A Phase II Study of Palbociclib plus Fulvestrant for pretreated patients with ER+/HER2- Metastatic Breast Cancer
| Cancers | |
|---|---|
| Organ | Breast |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 2 |
| Academic trial | Non |
| Sponsor | IBCSG |
| EudraCT Identifier | 2014-005387-15 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT02536742 |
| Inclusion criteria | ER+/HER2-. Metastatic. Endocrine resistant. Palbociclib |
| Last update |